February 10, 2026 01:09 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues | RG Kar scam twist: Court issues non-bailable warrant against whistle-blower Akhtar Ali | Court snub for Vijay: Madras HC rejects plea in ₹1.5 crore tax case

Pharmaceuticals dept visits USP India facility in Hyderabad

| | Feb 06, 2015, at 12:26 am
Hyderabad / Kolkata, Feb 5 (IBNS): Sudhansh Pant, Joint Secretary, Department of Pharmaceuticals (DoP), visited the US Pharmacopeia's (USP) state-of-the-art India facility in Hyderabad.
He toured the facility and met with senior level scientists. The purpose of this visit was to better understand the efforts USP is making in India to create standards for medicines, ensure full safety and quality of medicines and bring to India international standards in drug manufacture. 
 
India’s continued export growth in pharmaceuticals requires that every drug exported meets with the highest quality and safety requirements. USP is uniquely positioned to provide guidelines in this area.
                        
USP develops the reference standards to ensure the quality of Active Pharmaceutical Ingredients (APIs) and is supportive of government initiatives to strengthen and revive the domestic manufacturing of intermediaries and APIs.
 
The Joint Secretary’s discussion with USP India touched upon various aspects of ensuring the quality of medicines in India and how USP standards could help Indian manufacturers to import their products both to the US and to other countries.
 
Pant also enquired about the verification program and process and showed interest in the education and training programs conducted by USP. He was very impressed by the state-of-the-art facility and appreciated the quality and safety aspects maintained in the facility.
 
KV Surendranath, Senior Vice President- International Sites Operations said, “We welcome this opportunity to showcase our technical expertise to the Department of Pharmaceuticals. We see ourselves as partners in India’s efforts to produce safe and high quality medicines that meet all global standards. We hope to continue with future engagements with the DoP on various aspects related to quality of medicines and to address issues of critical importance to patient safety.”
 
Sudhansh Pant commented that he was very impressed and that the visit was quite enlightening and informative. He noted the commendable work being done at the facility in the field of standards, testing and research and the various collaborations in the interest of the Indian pharmaceutical industry. Mr. Pant hopes that other governments and private institutions will benefit from the presence of USP’s world class facility in Hyderabad.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.